Intracavernous injections: Past, present, and future

Article
  • 32 Downloads

Abstract

Intracavernous injection of vasoactive medications into the penis was the first available pharmacologic treatment developed to restore sexual function to men with erectile dysfunction. This paper relates this treatment’s history from the unique experience and perspective of the author, beginning in 1980 until now, using data involving nearly 7000 treated patients.

References and Recommended Reading

  1. 1.
    Virag R: Intracavernous injection of papaverine for erectile failure. Lancet 1982, 2:938.PubMedCrossRefGoogle Scholar
  2. 2.
    Virag R: Intracavernous perfusion for diabetic impotence. Presented at the Second International Conference on Corpus Cavernosum Revascularization. Monaco; May 1980.Google Scholar
  3. 3.
    Zorgniotti A, Lafleur W: Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol 1985, 133:39–41.PubMedGoogle Scholar
  4. 4.
    Brindley GS: Pilot experiments on the actions of drugs injected into the human corpus cavernosum. Br J Pharmacol 1986, 87:495–500.PubMedGoogle Scholar
  5. 5.
    1st World Meeting on Impotence records. Edited by Virag R. Les Editions du CERI; Paris; 1986.Google Scholar
  6. 6.
    Virag R: Trial of intracavernous papaverine in the treatment of impotence [in French]. J Mal Vasc 1983, 8:293–295.PubMedGoogle Scholar
  7. 7.
    Virag R, Shoukry K, Nollet F, Floresco J: Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-year experience with 615 cases. J Urol 1991, 145:287–292.PubMedGoogle Scholar
  8. 8.
    Bennett AH, Carpenter J, Barrada J: An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991, 146:1564–1565.PubMedGoogle Scholar
  9. 9.
    Virag R, Adaikan PG: Effects of prostaglandin E1 on penile erection and erectile failure. J Urol 1987, 137:1010.PubMedGoogle Scholar
  10. 10.
    Virag R: Les Injections Intracaverneuses. Paris: John Libbey-Eurotext; 2004.Google Scholar
  11. 11.
    Boolell M, Allen MJ, Ballard SA, et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996, 8:47–52.PubMedGoogle Scholar
  12. 12.
    Virag R: Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urol 1999, 54:1073–1077.PubMedCrossRefGoogle Scholar
  13. 13.
    Bachir D, Virag R, Galacteros F: Prevention and treatment of erectile disorders in sickle cell disease. Rev Med Interne 1997, 18(Suppl 1):46s–51s.PubMedCrossRefGoogle Scholar
  14. 14.
    Virag R, Bachir D, Floresco J, Dufour B: Ambulatory treatment and prevention of priapism using alpha-agonists. Chirurgie 1997, 121:648–652.PubMedGoogle Scholar
  15. 15.
    Melman A, Christ G: hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006, 17:1165–1176.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Centre d’exploration et traitement de l’ImpuissanceParisFrance

Personalised recommendations